OraSure Technologies (NASDAQ:OSUR) CFO Kenneth Mcgrath Acquires 32,300 Shares

OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Kenneth Mcgrath acquired 32,300 shares of the business’s stock in a transaction on Friday, March 20th. The stock was acquired at an average cost of $2.93 per share, with a total value of $94,639.00. Following the acquisition, the chief financial officer directly owned 589,562 shares in the company, valued at approximately $1,727,416.66. This trade represents a 5.80% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

OraSure Technologies Stock Up 4.4%

Shares of OSUR traded up $0.13 during mid-day trading on Monday, hitting $3.08. 778,783 shares of the company’s stock were exchanged, compared to its average volume of 592,308. OraSure Technologies, Inc. has a 52 week low of $2.08 and a 52 week high of $4.22. The stock’s 50-day simple moving average is $2.86 and its 200-day simple moving average is $2.78. The firm has a market cap of $212.92 million, a price-to-earnings ratio of -3.31 and a beta of 0.88.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The company had revenue of $26.76 million during the quarter, compared to the consensus estimate of $26.44 million. OraSure Technologies had a negative net margin of 59.76% and a negative return on equity of 16.45%. Analysts forecast that OraSure Technologies, Inc. will post -0.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of OraSure Technologies in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $3.00.

Institutional Investors Weigh In On OraSure Technologies

A number of large investors have recently modified their holdings of the business. Amundi acquired a new position in shares of OraSure Technologies during the 1st quarter worth $47,000. AQR Capital Management LLC boosted its stake in OraSure Technologies by 48.3% in the first quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier’s stock valued at $3,511,000 after buying an additional 339,493 shares in the last quarter. NewEdge Advisors LLC grew its position in OraSure Technologies by 32,595.9% in the first quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier’s stock valued at $161,000 after acquiring an additional 47,590 shares during the last quarter. Empowered Funds LLC raised its stake in OraSure Technologies by 7.2% during the first quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier’s stock worth $1,366,000 after acquiring an additional 27,310 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in OraSure Technologies by 32.7% during the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 8,133 shares in the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.